文献速递结核与非结核分枝杆菌

非结核分枝杆菌药敏试验新型外部质量评估方案:多中心试点研究

Novel external quality assurance scheme for drug susceptibility testing of non-tuberculous mycobacteria: a multicentre pilot study.
PubMed 文献 · J Antimicrob Chemother · 2019-01-01

本研究在欧洲结核参考实验室网络成员中开展问卷调查并实施试点外部质量评估(EQA),使用10株鸟分枝杆菌(MAV)和脓肿分枝杆菌(MAB)分离株的相同面板,16家采用肉汤微量稀释法的实验室返回结果。结果显示MAV和MAB的药敏试验基本一致性分别为78.8%-96.2%和76.0%-100%,分类一致性分别为56.8%-100%和53.6%-100%,表明实验室间重现性不足,需扩大EQA方案。

要点

  • 非结核分枝杆菌药敏试验的实验室间重现性不足
  • 鸟分枝杆菌和脓肿分枝杆菌的药敏基本一致性范围宽泛
  • 建议借鉴结核分枝杆菌复合群EQA经验推广至非结核分枝杆菌

核心结论

  • 非结核分枝杆菌药敏试验的实验室间重现性不足,需扩大外部质量评估方案。

研究设计与样本

  • 多中心试点研究,先以结构化问卷调查,后使用10株鸟分枝杆菌和脓肿分枝杆菌分离株的相同面板进行EQA轮次,16家采用肉汤微量稀释法的实验室返回结果。

主要发现

  • 鸟分枝杆菌基本一致性从78.8%(阿米卡星)到96.2%(利奈唑胺),分类一致性从56.8%(莫西沙星)到100%(克拉霉素)。
  • 脓肿分枝杆菌基本一致性从76.0%(阿米卡星)到100%(多西环素),分类一致性从53.6%(利奈唑胺)到100%(多西环素)。

临床怎么用

  • 临床微生物实验室应参与非结核分枝杆菌药敏试验的外部质量评估以提升结果可靠性。
  • 对鸟分枝杆菌和脓肿分枝杆菌的药敏结果解读需考虑实验室间差异。

局限性

  • 仅16家实验室返回EQA结果,样本量有限。
  • 仅评估肉汤微量稀释法,未涵盖其他药敏方法。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Our aim was to conduct a multicentre study involving laboratories participating in the European TB Reference Laboratory Network aiming to develop a pilot external quality assessment (EQA) scheme for drug susceptibility testing (DST) of non-tuberculous mycobacteria (NTM). METHODS: The study comprised a survey using a structured questionnaire followed by a pilot EQA round using identical panels of 10 Mycobacterium avium (MAV) and Mycobacterium abscessus (MAB) isolates. EQA results were received from 16 laboratories utilizing the broth microdilution method. Consensus modal MIC values were determined, and essential and categorical agreement rates were calculated. RESULTS: Twenty-four out of 31 laboratories (77.4%) reported DST for NTM routinely. Essential agreement ranged from 78.8% (amikacin) to 96.2% (linezolid) for MAV and from 76.0% (amikacin) to 100% (doxycycline) for MAB. Categorical agreement ranged from 56.8% (moxifloxacin) to 100% (clarithromycin) for MAV and from 53.6% (linezolid) to 100% (doxycycline) for MAB. CONCLUSIONS: Our results show that interlaboratory reproducibility of DST for NTM is insufficient, highlighting the need for expanding EQA schemes. As EQAs for Mycobacterium tuberculosis complex have led to more reliable and reproducible DST, we propose to follow a similar approach for clinically relevant NTM.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Nikolayevskyy V, Maurer FP, Holicka Y, et al. Novel external quality assurance scheme for drug susceptibility testing of non-tuberculous mycobacteria: a multicentre pilot study. J Antimicrob Chemother. 2019. PMID: 30753511. doi:10.1093/jac/dkz027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。